News | FDA | February 02, 2024

Edwards’ EVOQUE Valve Replacement System First Transcatheter Therapy Earns FDA Approval for Tricuspid Valve

Edwards Lifesciences Corporation announced the company’s EVOQUE tricuspid valve replacement system is the first transcatheter therapy to receive U.S. Food and Drug Administration (FDA) approval for the treatment of tricuspid regurgitation (TR). The EVOQUE system is indicated for the improvement of health status in patients with symptomatic severe TR despite optimal medical therapy (OMT), for whom tricuspid valve replacement is deemed appropriate by a heart team.

The EVOQUE system is indicated for the improvement of health status in patients with symptomatic severe TR despite optimal medical therapy (OMT), for whom tricuspid valve replacement is deemed appropriate by a heart team.

Edward Lifesciences Corporation announced the company’s EVOQUE tricuspid valve replacement system is the first transcatheter therapy to receive U.S. Food and Drug Administration (FDA) approval for the treatment of tricuspid regurgitation (TR). Photo courtesy: Edwards Lifesciences


February 2, 2024 — Edwards Lifesciences Corporation announced the company’s EVOQUE tricuspid valve replacement system is the first transcatheter therapy to receive U.S. Food and Drug Administration (FDA) approval for the treatment of tricuspid regurgitation (TR). The EVOQUE system is indicated for the improvement of health status in patients with symptomatic severe TR despite optimal medical therapy (OMT), for whom tricuspid valve replacement is deemed appropriate by a heart team.

“Edwards has a long history of leading innovation and pioneering new therapies to address the unmet needs of patients with structural heart disease,” said Daveen Chopra, Edwards’ corporate vice president, transcatheter mitral and tricuspid therapies. “We are grateful for the strong collaboration with clinicians all over the world who contributed to the EVOQUE system now being available through FDA’s Breakthrough Pathway to provide a treatment option to the many patients in the US suffering with tricuspid valve disease.”

The EVOQUE system is comprised of a nitinol self-expanding frame, intra-annular sealing skirt and tissue leaflets made from the company’s proven bovine pericardial tissue. The EVOQUE valve will be available in three sizes, all delivered through the same low-profile transfemoral 28F system.

“Patients suffering with tricuspid regurgitation endure life-impairing symptoms and, until today, had no approved transcatheter treatment options,” said Susheel Kodali, MD, director, Structural Heart and Valve Center at Columbia University Irving Medical Center/New York-Presbyterian Hospital and TRISCEND II Study Principal Investigator. “The EVOQUE system is able to replace the native tricuspid valve, virtually eliminating tricuspid regurgitation in a wide range of patients. We see significant improvements in patients’ symptoms and quality-of-life, including not feeling short of breath and being able to care for themselves, which ranked highest on a patient preference survey conducted at baseline with TRISCEND II pivotal trial patients.”

Successful six-month results from the randomized controlled pivotal trial, TRISCEND II, were presented at TCT 2023 and reported favorable safety and effectiveness outcomes, demonstrating superiority to OMT alone and meeting all primary endpoints. Key findings in the trial included significant reduction or elimination of tricuspid regurgitation and significant and sustained quality of life improvement, while demonstrating a favorable balance between risk and benefit.

In addition to the six-month cohort, 318 of the total 392 randomized patients completed a 1-year visit. The results showed favorable trends in the device group compared to the control group in the primary composite endpoints, including all-cause mortality, tricuspid intervention, heart failure hospitalization, KCCQ, NYHA and 6MWD. Edwards expects to present the full cohort of 392 TRISCEND II pivotal trial patients at TCT 2024.

The EVOQUE system received CE Mark approval in October 2023, making it the world’s first transcatheter valve replacement therapy to receive regulatory approval to treat TR.

For more information: www.edwards.com

RELATED CONTENT: 

Edwards Evoque Transcatheter Tricuspid Valve Replacement System Receives CE Mark

Edwards Announces One-year Data on Transfemoral Transcatheter Tricuspid Valve Replacement 

Six-Month Outcomes Positive for Transfemoral Tricuspid Valve in Tricuspid Regurgitation Patients 

Edwards LifeSciences Reports Positive Clinical Updates on its Transcatheter Mitral and Tricuspid Valves 


Related Content

News | FDA

June 18, 2024 — Elixir Medical has announced the company’s novel bioadaptive implant, DynamX Sirolimus-Eluting Coronary ...

Home June 18, 2024
Home
News | FDA

June 17, 2024 — Elutia Inc., a pioneer in drug-eluting biomatrix products, today announced that its Antibiotic-Eluting ...

Home June 17, 2024
Home
News | FDA

June 13, 2024 — Xeltis, a leading developer of transformative implants that enable the natural creation of living and ...

Home June 13, 2024
Home
News | FDA

June 3, 2024 — Heuron, a specialized medical AI startup focused on brain and neurological disorders based in South Korea ...

Home June 03, 2024
Home
News | FDA

May 17, 2024 — Implicity, a leader in remote patient monitoring and cardiac data management solutions, announced it has ...

Home May 17, 2024
Home
News | FDA

May 15, 2024 — The U.S. Food and Drug Administration (FDA) announced that Abbott is recalling the HeartMate 3 LVAS by ...

Home May 15, 2024
Home
News | FDA

May 8, 2024 — The US Food and Drug Administration (FDA) is alerting health care providers and facilities about our ...

Home May 08, 2024
Home
News | FDA

May 8, 2024 — 4C Medical Technologies, Inc. ("4C Medical"), a medical device company dedicated to advancing minimally ...

Home May 08, 2024
Home
News | FDA

May 7, 2024 — RapidAI, the global leader in developing clinically deep Artificial Intelligence (AI) and technology ...

Home May 07, 2024
Home
News | FDA

April 25, 2024 — Provisio Medical announced FDA 510(k) clearance of the Provisio SLT IVUS System. Sonic Lumen Tomography ...

Home April 25, 2024
Home
Subscribe Now